GEWICHT: 57 kg
Brüste: 75 A natur
Services: Paare, Korperbesamung, Stellung 69, Leidenschaftliches Kussen, Leidenschaftliches Kussen
Development of novel diagnostic and therapeutic approaches to improve patient outcome in lung and pancreatic tumours. Calle Melchor Fernandez Almagro 3 Madrid. Research Organisations. Sito web. Contatto amministrativo. Dolores Liebanes Dr. Classifica in ordine alfabetico. Classifica per Contributo UE. Espandi tutto. Regno Unito. Le previsioni correnti indicano che il cancro ai polmoni e al pancreas saranno le principali cause di morte per malattie tumorali nei prossimi decenni. Biosintesi dei lipidi, cancro al pancreas, cancro ai polmoni, resistenza, ciclo di Kennedy, colina chinasi.
Editore: Public Library of Science ID permanente: doi Autori: Molina-Montes, E. Editore: Oxford University Press ID permanente: pmc:PMC,doi ID permanente: pmc:PMC,pmid,doi Autori: Gerdtsson, Anna S.
This involves better tools for diagnosis, prognosis, and selection of sensitive and resistant patients to current conventional therapies or improved innovative treatments as well as the development of novel therapeutic strategies. The major objective of this proposal is to improve management of patients with either lung or pancreatic tumors by studying the clinical applications of still not investigated metabolic and signalling pathways with the following aims: -development of new tools for early diagnosis -identification of novel tumour markers for early diagnosis and prognosis -prediction of response to conventional treatments -identification of the molecular mechanisms of generation of resistance -development of improved treatments based on the identification of novel molecular targets -design of novel anticancer strategies.
The proposed consortium is composed of four experimental research groups with a profound knowledge on molecular and cellular biology of cancer, and ample experience in the design of targeted and personalized cancer therapies along with translational research, complemented with three clinical groups with an extensive experience in the clinical management of lung and pancreatic cancer patients, guaranteeing a clinical proof-of principle and applicability, integrating basic-clinical European scientific excellence.